AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23072617 — intervention group
Group type: COMPARATOR
Intervention: Formula containing plant oils supplemented with arachidonic acid and docosahexaenoic acid
Number of subjects: 75
Study 23072617 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants (reference group)
Number of subjects: 75
Study 23072617 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulas
Number of subjects: 75
Study 19460106 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmol L(‐1) butyrate
Number of subjects: 11
Study 19460106 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mmol L(‐1) butyrate
Number of subjects: 11
Study 19460106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11
Study 17712121 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0557 1 mg/d plus sibutramine 10 mg/d
Number of subjects: 497
Study 17712121 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0557 1 mg/d plus orlistat 120 mg TID
Number of subjects: 497
Study 17712121 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine 10 mg/d
Number of subjects: 497
Study 17712121 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120 mg TID
Number of subjects: 497
Study 17712121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 17712121 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine alone
Number of subjects: 497
Study 17712121 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0557 + sibutramine
Number of subjects: 497
Study 17712121 — intervention group
Group type: COMPARATOR
Intervention: Orlistat alone
Number of subjects: 497
Study 17712121 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0557 + orlistat
Number of subjects: 497
Study 15117091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 0
Study 15117091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 15117091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg
Number of subjects: 0
Study 15117091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11803996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram bonded with Excite
Number of subjects: 24
Study 11803996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariston pHc bonded with Ariston Liner
Number of subjects: 24
Study 11803996 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Prime and Bond NT
Number of subjects: 24
Study 11803996 — intervention group
Group type: COMPARATOR
Intervention: Ariston pHc bonded with Excite
Number of subjects: 24
Study 9543158 — intervention group
Group type: COMPARATOR
Intervention: 375 IU urinary FSH, s.c., as a single injection on Day(LH+14) (group A; n = 11)
Number of subjects: 23
Study 9543158 — intervention group
Group type: COMPARATOR
Intervention: 75 IU daily from Day(LH+19) until Day(LH+23) (group B; n = 12)
Number of subjects: 23
Study 8058879 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed testing condition
Number of subjects: 56
Study 2973849 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion (2 pmol min‐1 kg‐1 for 3 h)
Number of subjects: 7
Study 29128897 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based SOP training (n = 30)
Number of subjects: 60
Study 29128897 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (n = 30)
Number of subjects: 60
Study 28827270 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy or meniscal repair followed by standard postsurgical care
Number of subjects: 140
Study 28827270 — intervention group
Group type: COMPARATOR
Intervention: 12-week individualised, supervised neuromuscular and strengthening exercise programme and patient education
Number of subjects: 140
Study 26021223 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 105
Study 26021223 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading
Number of subjects: 105
Study 26021223 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 105
Study 24302090 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session, simulation-based communication skills intervention (N=232)
Number of subjects: 472
Study 24302090 — intervention group
Group type: COMPARATOR
Intervention: Usual education (N=240)
Number of subjects: 472
Study 20862469 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose gadolinium contrast
Number of subjects: 29
Study 20862469 — intervention group
Group type: COMPARATOR
Intervention: Full-dose gadolinium contrast
Number of subjects: 29
Study 18442632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction mimetic therapy with metformin for 3 years
Number of subjects: 60
Study 16570675 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 0.25% ointment
Number of subjects: 330
Study 16570675 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (zinc oxide/petrolatum)
Number of subjects: 330
Study 12624492 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA + IFN
Number of subjects: 20
Study 12624492 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 20
Study 10030325 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10985
Study 10030325 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (diuretics, beta‐blockers)
Number of subjects: 10985
Study 10030325 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 10985
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 55
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy
Number of subjects: 55
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Isradipine + metoprolol/enalapril)
Number of subjects: 55
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 55
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 55
Study 1879388 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-influences-based drug prevention program (Midwestern Prevention Project)
Number of subjects: 5008
Study 6314747 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Number of subjects: 9
Study 6314747 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 9
Study 31914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthgrades certification reporting accuracy
Number of subjects: 500
Study 31914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean star rating
Number of subjects: 500
Study 31914115 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with 5-star ratings
Number of subjects: 500
Study 30019634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 100 mg/day plus intensive blood pressure treatment (targeted systolic blood pressure < 120 mmHg, monitored with a home blood pressure measuring device)
Number of subjects: 776
Study 30019634 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (no acetylsalicylic acid, targeted office systolic blood pressure < 140 mmHg, no home blood pressure measuring device)
Number of subjects: 776
Study 28490022 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (Concurrent Treatment with Prolonged Exposure)
Number of subjects: 110
Study 28490022 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT (Relapse Prevention Therapy)
Number of subjects: 110
Study 28490022 — intervention group
Group type: COMPARATOR
Intervention: AMCG (Active Monitoring Control Group)
Number of subjects: 110
Study 26633244 — intervention group
Group type: EXPERIMENTAL
Intervention: Kopstoring course (online 8-week group course with supervision by trained psychologists or social workers)
Number of subjects: 13
Study 26633244 — intervention group
Group type: EXPERIMENTAL
Intervention: Kopstoring course
Number of subjects: 13
Study 24260180 — intervention group
Group type: COMPARATOR
Intervention: Control arm of PATRICIA study
Number of subjects: 4825
Study 21131371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 125 mg i.v.
Number of subjects: 48
Study 18223010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0
Study 18223010 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 17022853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg b.i.d. with Metformin 1000 mg b.i.d.
Number of subjects: 13
Study 17022853 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg b.i.d. with Sitagliptin placebo
Number of subjects: 13
Study 17022853 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg b.i.d. with Metformin placebo
Number of subjects: 13
Study 17022853 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of Sitagliptin and Metformin
Number of subjects: 13
Study 14618553 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/d, flexibly dosed to 5-20 mg/d)
Number of subjects: 117
Study 14618553 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 mg/d, flexibly dosed to 5-20 mg/d)
Number of subjects: 117
Study 10846376 — intervention group
Group type: EXPERIMENTAL
Intervention: Black defendant
Number of subjects: 0
Study 10846376 — intervention group
Group type: EXPERIMENTAL
Intervention: White defendant
Number of subjects: 0
Study 10846376 — intervention group
Group type: EXPERIMENTAL
Intervention: Life without the possibility of parole
Number of subjects: 0
Study 10846376 — intervention group
Group type: EXPERIMENTAL
Intervention: Death penalty
Number of subjects: 0
Study 9589926 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy and aspirin (group I, n = 15)
Number of subjects: 127
Study 9589926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin only (group II, n = 49)
Number of subjects: 127
Study 9589926 — intervention group
Group type: COMPARATOR
Intervention: Control group (group III, n = 63)
Number of subjects: 127
Study 8227340 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I) 10 micrograms/kg.h
Number of subjects: 8
Study 8227340 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 3080892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (50 micrograms followed by 100 micrograms on the second day)
Number of subjects: 22
Study 3080892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (25 micrograms followed by 50 micrograms)
Number of subjects: 22
Study 3080892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (25 and 50 micrograms)
Number of subjects: 22
Study 3080892 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 22
Study 3080892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 22
Study 3080892 — intervention group
Group type: COMPARATOR
Intervention: Both Pergolide and Bromocriptine
Number of subjects: 22
Study 31868008 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain relief
Number of subjects: 81
Study 31868008 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional analgesic treatment)
Number of subjects: 81
Study 28673512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready! Set? Let's Train! (RST)
Number of subjects: 17
Study 28673512 — intervention group
Group type: COMPARATOR
Intervention: Homework Assistance (HWA)
Number of subjects: 17
Study 26874683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT-Cognitive Only)
Number of subjects: 63
Study 25385727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 40 mg/m² IV on days 1 to 3
Number of subjects: 637
Study 25385727 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m² IV on days 1 to 5
Number of subjects: 637
Study 25385727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin
Number of subjects: 637
Study 25385727 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 637
Study 23524911 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake (energy%)
Number of subjects: 1319
Study 20578378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Shenshu (BL 23), Qihaishu (BL 24), Dachangshu (BL 25), and Pishu (BL 20) for 2 weeks
Number of subjects: 21
Study 20578378 — intervention group
Group type: COMPARATOR
Intervention: Basic neurology therapies (Control group)
Number of subjects: 21
Study 17554753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0
Study 17554753 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 16891991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate infusion therapy
Number of subjects: 11
Study 16891991 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients with Paget's disease)
Number of subjects: 11
Study 14702670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV) diagnosed by Gram stain
Number of subjects: 179
Study 14702670 — intervention group
Group type: COMPARATOR
Intervention: Normal microflora
Number of subjects: 179
Study 14702670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological culture
Number of subjects: 179
Study 14702670 — intervention group
Group type: EXPERIMENTAL
Intervention: C. trachomatis infection
Number of subjects: 179
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9194
Study 10950398 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded study drug alone
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded drug plus hydrochlorothiazide (HCTZ)
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded drugs plus HCTZ and additional drugs
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: US patients
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously untreated patients
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 9194
Study 10950398 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 9194
Study 8978804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (1,200 mg/day) administered preoperatively for 7 to 14 days
Number of subjects: 60
Study 1442991 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous placental delivery
Number of subjects: 62
Study 1442991 — intervention group
Group type: COMPARATOR
Intervention: Manual placental delivery
Number of subjects: 62
Study 3519193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic paravariceal injection sclerotherapy (group IB)
Number of subjects: 71
Study 3519193 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group IA)
Number of subjects: 71
Study 3519193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic paravariceal injection sclerotherapy (group II)
Number of subjects: 71
Study 3519193 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular monitoring and re-injection (group II)
Number of subjects: 71
Study 31988643 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-curricular activities on reproductive health (seminars)
Number of subjects: 400
Study 31988643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra-curricular activities)
Number of subjects: 400
Study 29723995 — intervention group
Group type: EXPERIMENTAL
Intervention: ILAV A (4.68 percent body weight)
Number of subjects: 0
Study 29723995 — intervention group
Group type: EXPERIMENTAL
Intervention: ILAV B (4.05 percent body weight)
Number of subjects: 0
Study 29723995 — intervention group
Group type: EXPERIMENTAL
Intervention: ILAV C (3.71 percent body weight)
Number of subjects: 0
Study 29723995 — intervention group
Group type: COMPARATOR
Intervention: Normal station wear
Number of subjects: 0
Study 27550880 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser acupuncture
Number of subjects: 62
Study 27550880 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 62
Study 21534678 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-based educational leaflet and action planning intervention
Number of subjects: 201
Study 21534678 — intervention group
Group type: COMPARATOR
Intervention: Standard government information leaflet
Number of subjects: 201
Study 15659494 — intervention group
Group type: EXPERIMENTAL
Intervention: DF (docetaxel 75 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Number of subjects: 90
Study 15659494 — intervention group
Group type: COMPARATOR
Intervention: ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Number of subjects: 90
Study 12196334 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Sr/90Y beta-radiation
Number of subjects: 476
Study 12196334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study 9669790 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 24
Study 8308973 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 70
Study 8308973 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 70
Study 3181098 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg), retinol (15 mg), and zinc (50 mg) supplement
Number of subjects: 610
Study 3181098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D-mannitol)
Number of subjects: 610
Study 4369018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 4369018 — intervention group
Group type: COMPARATOR
Intervention: Upright posture
Number of subjects: 0
Study 4369018 — intervention group
Group type: COMPARATOR
Intervention: Recumbent and upright positions
Number of subjects: 0
Study 4369018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 0
Study 11773179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranpirnase (Onconase; Alfacell Corp, Bloomfield, NJ), single weekly intravenous dose
Number of subjects: 105
Study 31257186 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal patella lead exposure
Number of subjects: 248
Study 30195953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of immobilization in a simple sling
Number of subjects: 120
Study 30195953 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of immobilization in a brace with a small abduction pillow
Number of subjects: 120
Study 27438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole addition (adding aripiprazole to previous antipsychotics)
Number of subjects: 52
Study 27438182 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole switching (switching previous antipsychotics to aripiprazole)
Number of subjects: 52
Study 25416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) over a one-month period.
Number of subjects: 89
Study 25416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) in women.
Number of subjects: 89
Study 25416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem) in men.
Number of subjects: 89
Study 25416480 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from benzodiazepines (temazepam, zopiclone, zolpidem).
Number of subjects: 89
Study 25416480 — intervention group
Group type: COMPARATOR
Intervention: Non-withwithdrawers (reduced benzodiazepine use).
Number of subjects: 89
Study 22507886 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids (1350 mg of eicosapentaenoic acid and 850 mg of docosahexaenoic acid daily)
Number of subjects: 92
Study 22507886 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 92
Study 21409920 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 'A' clopidogrel 600 mg
Number of subjects: 35
Study 21409920 — intervention group
Group type: COMPARATOR
Intervention: Brand 'B' clopidogrel 600 mg
Number of subjects: 35
Study 17961722 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous transplantation of hematopoietic stem cells (HDT/ASCT)
Number of subjects: 0
Study 17961722 — intervention group
Group type: COMPARATOR
Intervention: Optimal chemoimmunotherapy
Number of subjects: 0
Study 15505637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic meal
Number of subjects: 12
Study 15505637 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic meal
Number of subjects: 12
Study 11950190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment (oestradiol valerate 2mg once daily)
Number of subjects: 55
Study 11950190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9585678 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, clarithromycin 250 mg twice daily)
Number of subjects: 67
Study 9585678 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, metronidazole 500 mg twice daily)
Number of subjects: 67
Study 9585678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 67
Study 8607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tonsillar spray with 10% lidocaine 4 mg kg‐1 3 minutes before surgical incision
Number of subjects: 75
Study 8607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tonsillar spray with 10% lidocaine after both tonsils had been removed
Number of subjects: 75
Study 8607304 — intervention group
Group type: COMPARATOR
Intervention: No topical spray (control group)
Number of subjects: 75
Study 8607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (both pre- and postoperative)
Number of subjects: 75
Study 8607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative lidocaine
Number of subjects: 75